TABLE OF CONTENTS

1 INTRODUCTION 11
1.1 OBJECTIVES OF THE STUDY 11
1.2 MARKET DEFINITION 11
1.3 SCOPE OF THE STUDY 12
1.3.1 YEARS CONSIDERED FOR THE STUDY 12
1.3.2 CURRENCY 13
1.4 LIMITATIONS 13
1.5 STAKEHOLDERS 13
2 RESEARCH METHODOLOGY 14
2.1 RESEARCH DATA 14
2.1.1 SECONDARY DATA 15
2.1.1.1 Key secondary sources 15
2.1.2 PRIMARY DATA 15
2.1.2.1 Breakdown of Primary Interviews, by Company Type, Designation, and Region 16
2.1.3 KEY DATA FROM PRIMARY SOURCES 16
2.2 MARKET SIZE ESTIMATION 17
2.2.1 BOTTOM-UP APPROACH 17
2.2.2 TOP-DOWN APPROACH 18
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 19
2.4 ASSUMPTIONS FOR THE STUDY 20
3 EXECUTIVE SUMMARY 21
4 PREMIUM INSIGHTS 24
4.1 ATTRACTIVE OPPORTUNITIES IN THE RSV DIAGNOSTICS MARKET 24
4.2 GEOGRAPHIC ANALYSIS: RSV DIAGNOSTICS MARKET, BY PRODUCT & REGION (2017) 25
4.3 RSV DIAGNOSTICS MARKET, BY END USERS, 2017–2022 26
4.4 GEOGRAPHICAL SNAPSHOT OF THE RSV DIAGNOSTICS MARKET 26
5 MARKET OVERVIEW 27
5.1 INTRODUCTION 27
5.2 MARKET DYNAMICS 27
5.2.1 DRIVERS 28
5.2.1.1 Increasing burden of RSV infections 28
5.2.1.2 Growing demand for point-of-care molecular diagnostic tests for the diagnosis of RSV infections 29
5.2.1.2.1 Increasing adoption of molecular diagnostics over immunoassays 29
5.2.1.3 Increasing approval of RSV diagnostic kits and assays 30
5.2.2 RESTRAINTS 30
5.2.2.1 Low detection limits of immunoassays 30
5.2.3 OPPORTUNITIES 30
5.2.3.1 Technological advancements in diagnostic methods 30
5.2.4 THREATS 31
5.2.4.1 Development of RSV vaccines 31
6 RSV DIAGNOSTICS MARKET, BY PRODUCT 32
6.1 INTRODUCTION 33
6.2 KITS AND ASSAYS 34
6.3 INSTRUMENTS 35
6.4 OTHER PRODUCTS 37
7 RSV DIAGNOSTICS MARKET, BY METHOD 39
7.1 INTRODUCTION 40
7.2 MOLECULAR DIAGNOSTICS 41
7.3 RAPID ANTIGEN DETECTION TESTS 42
7.3.1 ENZYME-LINKED IMMUNOSORBENT ASSAYS 44
7.3.2 IMMUNOFLUORESCENCE ASSAYS 45
7.3.3 OTHER RAPID ANTIGEN DETECTION TESTS 47
7.3.3.1 Chromatographic immunoassays 48
7.3.3.2 Optical immunoassays 50
7.4 OTHER METHODS 51
8 RSV DIAGNOSTICS MARKET, BY END USER 53
8.1 INTRODUCTION 54
8.2 HOSPITALS AND CLINICS 55
8.3 CLINICAL LABORATORIES 56
8.4 HOME CARE 57
9 RSV DIAGNOSTICS MARKET, BY REGION 59
9.1 INTRODUCTION 60
9.2 NORTH AMERICA 61
9.2.1 US 64
9.2.2 CANADA 66
9.3 EUROPE 67
9.3.1 GERMANY 70
9.3.2 UK 71
9.3.3 FRANCE 73
9.3.4 REST OF EUROPE 74
 
9.4 APAC 76
9.5 ROW 79
10 COMPETITIVE LANDSCAPE 81
10.1 INTRODUCTION 81
10.2 MARKET OVERVIEW 81
10.3 MARKET SHARE ANALYSIS, 2016 82
10.4 COMPETITIVE SCENARIO 83
10.4.1 PRODUCT LAUNCHES AND APPROVALS 83
10.4.2 ACQUISITIONS 83
10.4.3 AGREEMENTS AND COLLABORATIONS 84
10.4.4 EXPANSIONS 84
11 COMPANY PROFILES 85
Business Overview, Products Offered, Recent Developments, MNM View
11.1 BIOMÉRIEUX 85
11.2 BECTON, DICKINSON AND COMPANY (BD) 87
11.3 ABBOTT 89
11.4 ROCHE 91
11.5 DANAHER 93
11.6 THERMO FISHER 95
11.7 BIOCARTIS 97
11.8 LUMINEX 99
11.9 HOLOGIC 101
11.10 FAST TRACK DIAGNOSTICS 103
*Details might not be captured in case of unlisted companies.
12 APPENDIX 104
12.1 INDUSTRY INSIGHTS 104
12.2 DISCUSSION GUIDE 105
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 108
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 110
12.5 AVAILABLE CUSTOMIZATIONS 111
12.6 RELATED REPORTS 112
12.7 AUTHOR DETAILS 113